- Home
- INVE vs AVTX Comparison
INVE vs AVTX Comparison
Compare INVE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | AVTX |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 339.9M |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | INVE | AVTX |
|---|---|---|
| Price | $3.69 | $14.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $39.33 |
| AVG Volume (30 Days) | 137.4K | ★ 823.9K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | $27,813,137.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.21 | ★ 2312.27 |
| 52 Week Low | $2.98 | $3.39 |
| 52 Week High | $4.08 | $20.72 |
Technical Indicators
Market Signals| Indicator | INVE | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 44.60 |
| Support Level | $3.25 | $13.38 |
| Resistance Level | $3.76 | $16.40 |
| Average True Range (ATR) | 0.24 | 1.46 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 63.27 | 26.23 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).